1. Home
  2. HUIZ vs TCRX Comparison

HUIZ vs TCRX Comparison

Compare HUIZ & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Huize Holding Limited

HUIZ

Huize Holding Limited

SELL

Current Price

$2.10

Market Cap

12.6M

Sector

Finance

ML Signal

SELL

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

SELL

Current Price

$0.15

Market Cap

11.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
HUIZ
TCRX
Founded
2006
2018
Country
China
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.6M
11.8M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
HUIZ
TCRX
Price
$2.10
$0.15
Analyst Decision
Hold
Analyst Count
0
5
Target Price
N/A
★ $1.00
AVG Volume (30 Days)
25.4K
★ 420.2K
Earning Date
08-20-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 12.28
EPS
★ N/A
N/A
Revenue
N/A
★ $10,325,000.00
Revenue This Year
$6.27
N/A
Revenue Next Year
$11.13
N/A
P/E Ratio
$7.81
★ N/A
Revenue Growth
N/A
★ 266.65
52 Week Low
$1.04
$0.14
52 Week High
$3.83
$1.47

Technical Indicators

Market Signals
Indicator
HUIZ
TCRX
Relative Strength Index (RSI) 49.77 31.39
Support Level $1.52 N/A
Resistance Level $2.16 $0.21
Average True Range (ATR) 0.17 0.02
MACD -0.04 0.00
Stochastic Oscillator 27.66 8.07

Price Performance

Historical Comparison
HUIZ
TCRX

About HUIZ Huize Holding Limited

Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies that cooperate with the company, which the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers a digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners. Geographically, the company is concentrated in PRC Mainland, Hong Kong and others segments.

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Share on Social Networks: